BOSTON, June 10, 2025 /CNW/ -- Curadev Pharma, Inc., a clinical-stage biotechnology company developing novel immuno-oncology therapeutics, and Memorial Sloan Kettering Cancer Center (MSK), a ...

BOSTON and NOIDA, India, Feb. 15, 2024 /CNW/ -- Curadev is excited to introduce CRD3874, a first-in-class allosteric small molecule STING agonist, with distinct pharmacological properties that ...

Oakridge International School, Gachibowli Successfully Completes CIS Evaluation, Reinforcing Commitment to Global Excellence ...

STING is known to play a role in activating the innate immune system in auto-inflammatory diseases. Bayer and Curadev have announced a novel research collaboration and license agreement for Curadev’s ...

The immune checkpoint STING has seen some popularity as a target for cancer drug development, but Bayer and India’s Curadev have started working on STING drugs with potential in auto-immune and ...

NEW DELHI, India, April 20, 2015 -- Curadev Pharma Private Ltd. today announced that it has entered into a research collaboration and exclusive license agreement with Roche for the development and ...

NOIDA, India, Nov. 30, 2022 /PRNewswire/ -- For decades the growth of economies throughout the world has been primarily driven by the pursuit of scientific understanding, the application of ...

Noida (Uttar Pradesh) [India], October 25 (ANI/PRNewswire): Curadev's emphasis on education stems from its transformational effects on the individual and society at large. While education is of ...

Disclaimer: The following press release comes to you under an arrangement with PRNewswire. PTI takes no editorial responsibility for the same.) NOIDA, India, Jan. (Eds: Disclaimer: The following press ...

is excited to introduce CRD3874, a first-in-class allosteric small molecule STING agonist, with distinct pharmacological properties that distinguish it from agents that bind to STING's cGAMP site. An ...